Takeda decided to end development for a fixed-dose combination of diabetes drug, Actos (pioglitazone), plus hypertension compound, TAK-536. The decision was reached after the company found that the late-stage candidate would require an "improvement in pharmaceutical formulation." The drugmaker did not elaborate on the formulation issues.
Additionally, Takeda said it conducted a review of its investigational cardiovascular and diabetes drugs and concluded that "it is optimal to prioritise projects other than Actos plus TAK-536 in order to provide novel treatment options as early as possible."
To read more Top Story articles, click here.